Viridian Therapeutics Enters Material Definitive Agreement
Ticker: VRDN · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1590750
Sentiment: neutral
Topics: material-definitive-agreement
TL;DR
Viridian Therapeutics signed a big deal, details TBD.
AI Summary
Viridian Therapeutics, Inc. announced on September 11, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement, its terms, or any associated financial figures.
Why It Matters
This filing indicates a significant business development for Viridian Therapeutics, potentially impacting its operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the material definitive agreement.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- September 11, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Viridian Therapeutics?
The filing states that Viridian Therapeutics entered into a Material Definitive Agreement on September 11, 2024, but does not provide specific details about the agreement itself.
Are there any financial terms or dollar amounts associated with this agreement disclosed in the filing?
No, the filing does not disclose any specific financial terms or dollar amounts related to the Material Definitive Agreement.
When was the Material Definitive Agreement entered into?
The Material Definitive Agreement was entered into on September 11, 2024.
What is the company's state of incorporation?
Viridian Therapeutics, Inc. is incorporated in Delaware.
What is the IRS Employer Identification Number for Viridian Therapeutics?
The IRS Employer Identification Number for Viridian Therapeutics is 47-1187261.
Filing Stats: 1,239 words · 5 min read · ~4 pages · Grade level 13.3 · Accepted 2024-09-12 17:25:59
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value VRDN The Nasdaq Stock Mar
- $18.75 — Stock"), at a public offering price of $18.75 per share, and, in lieu of shares of th
- $1,250.06250 — d Stock") at a public offering price of $1,250.06250 per share. In addition, the Company gra
- $258.8 m — any from the Offering are approximately $258.8 million, which includes the gross proceed
Filing Documents
- d881013d8k.htm (8-K) — 32KB
- d881013dex11.htm (EX-1.1) — 251KB
- d881013dex51.htm (EX-5.1) — 5KB
- g881013g0912232630868.jpg (GRAPHIC) — 3KB
- 0001193125-24-218131.txt ( ) — 486KB
- vrdn-20240911.xsd (EX-101.SCH) — 3KB
- vrdn-20240911_lab.xml (EX-101.LAB) — 18KB
- vrdn-20240911_pre.xml (EX-101.PRE) — 11KB
- d881013d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or other similar terms or expressions that concern the Company's expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on the Company's current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: the anticipated closing of the Offering and the Company's expected cash runway. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: other matters that could affect the sufficiency of existing cash, cash equivalents and short-term investments to fund operations; the Company's financial position and its projected cash runway; the Company's future operating results and financial performance; and market conditions and satisfaction of customary closing conditions related to the Offering. There can be no assurance that the Company will be able to complete the Offering on the anticipated terms, or at all. Applicable risks also include those risks set forth under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 8, 2024 and other subsequent disclosure documents filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neithe
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits . Exhibit Number Exhibit Description 1.1 Underwriting Agreement, by and among the Company and the Representatives, dated as of September 11, 2024 5.1 Opinion of Ropes & Gray LLP 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viridian Therapeutics, Inc. Date: September 12, 2024 By: /s/ Stephen Mahoney Stephen Mahoney President, Chief Executive Officer, and Director